Supplementary Table 3. Alterations detected by ctDNA sequencing

	Patient 1		Patient 2		Patient 3			
Timing for FGFR inhibition	Pretreatment		Pretreatment		Pretreatment		Postprogression	
Amplification	Alterations	pCN	Alterations	pCN	Alterations	pCN	Alterations	pCN
	FGFR2 *ERBB2* *CDK4* *CCND1* *CCNE1*	24.2 2.5 9.5 2.3 2.3	*FGFR2*	6.0	*FGFR2* *MET*	14.6 3.0	*FGFR2* amp *MET* *KRAS*	7.3 15.7 2.4
Actionable mutations	Alterations	VAF (%)	Alterations	VAF (%)	Alterations	VAF (%)	Alterations	VAF (%)
	NF1 splice site SNV *TP53* G245S	0.2 28.8	*APC* E1257* *APC* T1556fs *ARID1A* L1731*	0.8 0.6 2.2	*CTNNB1* S37F *TP53* R213* *ARID1A* W1023*	0.8 12.2 1.5	*CTNNB1* S37F *TP53* R213* *ARID1A* W1023*	13.2 49.3 26.1
Actionable fusions	Alterations	VAF (%)	Alterations	VAF (%)	Alterations	VAF (%)	Alterations	VAF (%)
	FGFR2-TACC2	0.1						
VUS or synonymous mutations	Alterations	VAF (%)	Alterations	VAF (%)	Alterations	VAF (%)	Alterations	VAF (%)
	BRCA1 N682Y *BRCA1* S681I	4.5 4.4	*FGFR2* L763L *EGFR* L249L	0.7 0.2	*EGFR* P518L *ARAF* P483P	1.4 3.5	*EGFR* P518L *ARAF* P483P	13.8 0.15

Abbreviations: ctDNA, circulating tumor DNA; pCN, plasma copy number; amp, amplification; VAF, variant allele frequency; SNV, single nucleotide variant; VUS, variant of unknown significance.